Atrial Fibrillation and Heart Failure as the Onset of AL-Amyloidosis

Left ventricular hypertrophy, atrial fibrillation and chronic heart failure are often in the practice of a cardiologist. The etiology of these conditions is very important because the correct early treatment. We are presenting a case of a late diagnosis of amyloidosis in a 53-year-old man. Despite the complex therapy, the course of the disease was complicated by the development of bilateral pneumonia, sepsis, disseminated intravascular coagulation and the patient died. Autopsy confirmed the diagnosis of systemic AL-amyloidosis (type Kappa) with massive damage to the heart, kidneys, lungs, liver, spleen, adrenal glands, thyroid gland, pancreas, gastrointestinal tract, subcutaneous fatty tissue and arterial vessels of the bone marrow. Thus, screening for amyloidosis is necessary in idiopathic LV thickening, atrial fibrillation, and heart failure for timely intravital diagnosis and therapy.

1. Rysava R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019; 34(9): 1460-6. doi: 10.1093/ndt/gfy291. PubMed PMID: 30299492.

2. Kristen AV, Perz JB, Schonland SO et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant. 2007; 26(12): 1313-9. doi: 10.1016/j.healun.2007.09.014. PubMed PMID: 18096484.

3. Dubrey SW, Cha K, Anderson J et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998; 91(2): 141-57. doi: 10.1093/qjmed/91.2.141. PubMed PMID: 9578896.

4. Karafiatova L, Pika T. Amyloid cardiomyopathy. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2017; 161(2): 117-27. doi: 10.5507/bp.2017.001. PubMed PMID: 28145535.

5. Reznik E.V., Nguyen T.L., Stepanova E.A. et al. Cardiac Amyloidosis: Internist and Cardiologist Insight. The Russian Archives of Internal Medicine. 2020; 10(6): 430-457. https://doi.org/10.20514/2226-6704-2020-10-6-430-457 [In Russian].

6. Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev S. et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Therapy. 2020; 29(1): 13-24. DOI 10.32756/ 0869-5490-2020-1-13-24 [In Russian]

7. Резник Е.В., Степанова E.A., Нгуен Т. и др. Ретроспективный анализ поражения сердечно-сосудистой системы у пациентов системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021; 20(1): 2496. Reznik E.V., Stepanova E.A., Nguyen T. et al. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021; 20(1): 2496. [In Russian]

8. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016; 68(12): 1323-41. doi: 10.1016/j.jacc.2016.06.053. PubMed PMID: 27634125.

9. Reznik E.V., Nikitin I.G. Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part 2): prognosis, prevention and treatment. The Russian Archives of Internal Medicine. 2019; 9(2): 93-106. doi: 10.20514/2226-6704-2019-9-2-93-106 [In Russian]

10. Reznik E.V., Nikitin I.G. Сardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019; 9(1): 5-22. doi: 10.20514/2226-6704-2019-9-1-5-22 [In Russian]

11. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. British journal of haematology. 2015; 168(2): 186-206. doi: 10.1111/bjh.13155. PubMed PMID: 25303672.

12. Kastritis E, Dimopoulos MA. Recent advances in the management of AL Amyloidosis. British journal of haematology. 2016; 172(2): 170-86. doi: 10.1111/bjh.13805. PubMed PMID: 26491974.

13. Fajardo J, Cummings A, Brown E et al. Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2019; 26(sup1): 166-7. doi: 10.1080/13506129.2019.1583178. PubMed PMID: 31343333.